FNIH Announces FDA Qualification of First Surrogate Endpoint for Use in Osteoporosis Clinical Trials

FNIH Announces FDA Qualification of First Surrogate Endpoint for Use in Osteoporosis Clinical Trials

NORTH BETHESDA, Md.--(BUSINESS WIRE)--Dec 19, 2025-

BIDMC Investigator Contributes to FDA Approval of New and Better Way to Test Osteoporosis Treatments

There’s now a faster, more effective way to test new treatments for osteoporosis, and it is thanks in part to a decade-long effort led by Mary Bouxsein, PhD, a senior investigator in the Center for Advanced Orthopedic Studies at Beth Israel Deaconess Medical Center (BIDMC).